Srpt stock price after hours
SRPT After Hours Trading - SRPT Pre-Market - Sarepta ... SRPT After Hours Trading and Pre-Market Trading After-Hours Trades Nasdaq.com provides detailed information on the last after hours trades on a stock as well as on the after hours high and low price, trading in the after hours market from 4:00 till 8:00 p.m. ET SRPT Stock Price, Forecast & News (Sarepta Therapeutics) Analyzing Sarepta Therapeutics (NASDAQ:SRPT) stock? View SRPT's stock price, price target, earnings, financials, forecast, insider trades, news, and SEC filings at MarketBeat. Sarepta Therapeutics, Inc. (SRPT) Insider Trading Activity ... Stock Details Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain CHARTS Basic Chart Interactive Chart COMPANY NEWS Company Headlines Press Releases Market Stream STOCK ANALYSIS Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison FUNDAMENTALS Sarepta Therapeutics, Inc. (SRPT) Stock Forum & Discussion ...
SRPT Stock Quote - Sarepta Therapeutics, Inc. Stock Price ...
13 Dec 2019 Piper Jaffray analyst Danielle Brill raised her price target for Sarepta Therapeutics to $210 from $185 after Vyondys53, “in yet another surprise,” 20 Mar 2020 $SRPT so frustrating to see this stock go from relative strength after the in their portfolio. puke it all out , catch up with the market selloff, B.S.. today's stock price, news and analysis for Sarepta Therapeutics Inc. (SRPT). historical stock ratings, target prices, company earnings, market valuation and Detailed price information for Sarepta Therapeutics (SRPT-Q) from The Globe and Mail including Market movers: Stocks that saw action on Friday - and why. Sarepta Therapeutics. SRPT. Real-time BATS EXCHANGE - 03/09 04:03:55 pm. 104.155USD. -11.05%. Prev. 93.6200. Open, 98.2800. High, 99.5000.
Apr 03, 2020 · View today's stock price, news and analysis for Sarepta Therapeutics Inc. (SRPT). Barron's also provides information on historical stock ratings, target prices, company earnings, market valuation
Dec 12, 2019 · SRPT stock exploded up more than 27% in after-hours trading on December 12, 2019. SRPT stock explodes higher in after-hours trading (brown shaded area) on December 12, 2019. What caused SRPT stock to exploded higher was the news after market close today that the FDA approved VYONDYS 53™ (golodirsen). Sarepta Therapeutics (NASDAQ:SRPT) Ratings | Benzinga Jan 01, 2010 · Sarepta Therapeutics, Inc. (NASDAQ: SRPT) stock research, profile, news, analyst ratings, key statistics, fundamentals, stock price, charts, earnings, guidance and
Nov 08, 2019 · View today's stock price, news and analysis for Sarepta Therapeutics Inc. (SRPT). Barron's also provides information on historical stock ratings, target prices, company earnings, market valuation
Dec 12, 2019 · SRPT stock exploded up more than 27% in after-hours trading on December 12, 2019. SRPT stock explodes higher in after-hours trading (brown shaded area) on December 12, 2019. What caused SRPT stock to exploded higher was the news after market close today that the FDA approved VYONDYS 53™ (golodirsen).
Buy Sarepta Therapeutics Inc stock & View ($SRPT) Share ...
SRPT | Complete Sarepta Therapeutics Inc. stock news by MarketWatch. View real-time stock prices and SRPT U.S.: Nasdaq After Hours Volume: 27.2K. Find the latest Sarepta Therapeutics, Inc. (SRPT) stock quote, history, news and other Sarepta Therapeutics (SRPT) Down 8% Since Last Earnings Report: Can It Rebound We also told you to short the market ETFs and buy long-term […]. Extended Hours. Last Yield | 04/07/2020 XBI: Biotech ETF Expected To Outperform During And After The Coronavirus Pandemic · Mizuho sees 86% upside in 07 Apr 2020 4/6/2020 5:30 pm -- Open: 101.07 High: 101.07 Low: 99.00 Close: 99.00 1 / 1 90 95 100 105 0 250 500 750 1000 2020 Mar 2020 Apr 2020 Mar
Sarepta Therapeutics stock up 36% premarket after DMD drug approval MarketWatch. Thursday, December 12, 2019. 06:43 PM ET. Sarepta stock surges more than 20% as FDA finally OKs muscular dystrophy drug MarketWatch. Tuesday, December 03, 2019. 11:11 AM ET. Astellas’ $3 billion gene therapy deal steadies investors after stalled Roche acquisition